Book Review: Biomedical Innovation in Fertility Care – Evidence challenges, commercialisation and the market for hope
By Zeenat Beebeejaun,
PET
| 10. 28. 2024
Building on the 2016 BBC Panorama documentary 'Inside Britain's Fertility Business', which exposed the use of controversial fertility treatment add-ons in private fertility clinics (see BioNews 880), Manuela Perrotta's book, Biomedical Innovation in Fertility Care, unveils regulatory inadequacies that expose patients to abuse by the profit-driven medical industry. Perrotta makes a case for more ethical biomedical innovation in this book and proposes changes that put patients' interests and moral behaviour ahead of business interests.
In doing so, Perrotta explores the commercialisation of reproductive therapies, concentrating on the moral, practical, and legal problems that both experts and patients must deal with. The book criticises the marketing of reproductive treatment add-ons like EmbryoGlue and time-lapse imaging, which are portrayed as potential therapies for supporting pregnancies notwithstanding the lack of solid data proving their efficacy clinics (see BioNews 1240). This system presents serious ethical issues, especially when patients are asked to pay exorbitant costs for experimental procedures.
While reading the book, I found myself reflecting on how Perrotta highlights the restricted role of regulating authorities such as the Competition and...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...